You are here

FDA Announces Nationwide Recall by Compounding Pharmacy

All sterile non-expired products recalled due to lack of sterility assurance (Apr. 21)

The FDA has announced that Balanced Solutions Compounding Pharmacy, a division of Axium Healthcare Pharmacy, Inc., of Lake Mary, Fla., is voluntarily recalling all lots of its sterile non-expired drug products because of a lack of sterility assurance and concerns with product quality controls.

Health care facilities and health care providers that have received sterile products from Balanced Solutions should immediately check their medical supplies, quarantine the products, and follow the recall instructions from Balanced Solutions, the agency says. Patients who were administered any sterile drug products produced and distributed by Balanced Solutions and who have concerns should contact their health care providers.

During an FDA inspection of Balanced Solutions, investigators observed poor practices and conditions, which may have exposed the company’s sterile products to microbial contamination. The FDA’s preliminary findings of sterile production practices and conditions at the site raise concerns about a lack of sterility assurance. This lack of sterility assurance has been confirmed by further FDA analysis.

The FDA sampled chromium chloride injection from Balanced Solutions and identified gram-negative bacteria in the product. Gram-negative bacteria can cause disease and many types of infection, but the Sphingobacterium thalpophilum bacteria found in the solution do not usually cause infection in humans.

Source: FDA; April 21, 2013.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs